Navigating this stock for large hedgies has got to be some tricky waters at these low volumes. Anytime someone tries to cover the short bet, the PPS moves up significantly. There just aren't a lot of sellers here. So we see a low volume mostly sideways, maybe a small channel trade, kind of action. When the time comes that folks get serious about covering the 35M shorts, we'll see a very steady strong move up. That is when we'll see the end of this trading pattern. So when, if I may ask this most astute board, do the shorts get serious about covering? Do they wait until the very day of Comet readouts?
Cabozantinib in patients with progressive, metastatic medullary thyroid cancer (MTC).
The data were presented this weekend at the 2013 Annual Meeting of the
American Society of Clinical Oncology (ASCO). Long-term follow-up of a
phase 1 trial (Abstract #6090) shows that 30% of progressive, metastatic
MTC patients treated with COMETRIQ experienced disease control (DC) and
have remained progression-free for more than 2 years.
A RN and pharmd could single patient adjustments to increase that number.